NeoGenomics Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics or view top-rated stocks.

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

NeoGenomics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Wednesday, May 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NeoGenomics, Inc. (NASDAQ:NEO) posted its earnings results on Wednesday, February, 24th. The medical research company reported $0.14 EPS for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.08. The medical research company had revenue of $126 million for the quarter, compared to analysts' expectations of $123.45 million. NeoGenomics had a negative net margin of 1.16% and a positive trailing twelve-month return on equity of 0.71%. The business's revenue for the quarter was up 17.8% compared to the same quarter last year. During the same period last year, the business posted $0.06 EPS.
View NeoGenomics' earnings history.

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 99.1% and is now trading at $49.34.
View which stocks have been most impacted by COVID-19.

NeoGenomics declared a dividend on Tuesday, December 15th. Stockholders of record on Friday, December 18th will be given a dividend of $0.40 per share on Wednesday, December 30th. This represents a dividend yield of 3.13%. The ex-dividend date is Thursday, December 17th.
View NeoGenomics' dividend history.

11 brokers have issued 1 year target prices for NeoGenomics' shares. Their forecasts range from $14.50 to $65.00. On average, they anticipate NeoGenomics' stock price to reach $49.32 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts' price targets for NeoGenomics or view top-rated stocks among Wall Street analysts.

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to NeoGenomics include Cerner (CERN), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Fresenius Medical Care AG & Co. KGaA (FMS), Exact Sciences (EXAS), Sysmex (SSMXY), Genmab A/S (GNMSF), Straumann (SAUHF), 10x Genomics (TXG), Horizon Therapeutics Public (HZNP), CureVac (CVAC), Teleflex (TFX), Eisai (ESALY), Hologic (HOLX), NovoCure (NVCR) and The Cooper Companies (COO).
View all of NEO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.21%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%), Everence Capital Management Inc. (0.02%), NEXT Financial Group Inc (0.01%) and HMS Capital Management LLC (0.01%). Company insiders that own NeoGenomics stock include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, HMS Capital Management LLC, and Global Retirement Partners LLC. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics or view top insider-selling stocks.

NEO stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Everence Capital Management Inc., Louisiana State Employees Retirement System, and NEXT Financial Group Inc.
View insider buying and selling activity for NeoGenomics or or view top insider-buying stocks.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $49.34.

NeoGenomics has a market capitalization of $5.78 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis.

NeoGenomics employs 1,700 workers across the globe.

The official website for NeoGenomics is www.neogenomics.com.

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600 or via email at [email protected]